EUVIMEDDescoperă EUVIMED
Randomisierte kontrollierte StudieStudienprotokollOpen access

[177Lu]Lu-DOTATATE Molecular Radiotherapy During Induction Chemotherapy for First-Line Stage 4 High-Risk Neuroblastoma in South African Children: Protocol for a Phase 1 Randomized Controlled Trial (LuDO-SA Trial)

[177Lu]Lu-DOTATATE molekulare Radiotherapie während der Induktionschemotherapie bei Erstlinien-Stadium-4-High-Risk-Neuroblastom bei südafrikanischen Kindern: Protokoll einer randomisierten Phase-1-Studie (LuDO-SA-Studie)

Jaques van Heerden, Mariana Kruger, Kershinee Reddy, Anel van Zyl, James Warwick, Celeste Burger, Tumelo Moalosi, Christoffel van Reenen, Alan Davidson, Khanyisile Hlongwa, Daniella Violante, Nanette Bruwer and 7 more

JMIR Research Protocols · 2026-09-30 · 15 · e93547-e93547

DOI: 10.2196/93547 ↗

Auf einen Blick

Das Protokoll beschreibt eine Phase-1-Studie zu [177Lu]Lu-DOTATATE zusätzlich zur Induktionschemotherapie bei Kindern mit High-Risk-Neuroblastom. Berichtet werden Machbarkeit, Dosislimitierung und postinduktive Ansprechrate.

Fragestellung

Wie sicher, machbar und wirksam ist die Gabe von [177Lu]Lu-DOTATATE zusätzlich zur Standard-Induktionschemotherapie bei Kindern mit High-Risk-Neuroblastom?

Methode

Offene, multizentrische, randomisierte, kontrollierte Phase-1-Studie mit 2 Armen bei Kindern von 18 Monaten bis 18 Jahren; Vergleich von einmaligem [177Lu]Lu-DOTATATE nach Zyklus 1 mit Standardchemotherapie.

Ergebnisse

Zum Zeitpunkt Juli 2026 waren 15 Patient:innen an 4 akademischen Krankenhausstandorten eingeschlossen. Die Rekrutierung begann im Januar 2023; Abschluss ist für Juni 2027 geplant, Ergebnisse für Dezember 2027.

Schlussfolgerung der Autor:innen

Die Autor:innen stellen das Protokoll der LuDO-SA-Studie vor und beschreiben die Begründung, das Design, den Einsatz im Erstlinien-Setting und den aktuellen Stand der internationalen [177Lu]Lu-DOTATATE-Studien.

Kernaussagen

  • Protokoll einer offenen randomisierten Phase-1-Studie
  • Vergleich: [177Lu]Lu-DOTATATE plus Chemotherapie vs. Standardchemotherapie
  • Bisher 15 eingeschlossene Patient:innen an 4 Zentren

Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.

At a glance

Randomisierte kontrollierte Studie in JMIR Research Protocols, published online on 2026-09-30. Written by Jaques van Heerden and 18 co-authors. Institution: Department of Paediatrics and Child Health, Faculty of Medicine and Health Sciences, Tygerberg Hospital, Stellenbosch University, Stellenbosch Univer…. Major MEDLINE topics: Neuroblastoma, Octreotide, Induction Chemotherapy, Organometallic Compounds. 32 references. The full text is freely available in PubMed Central.

Auf einen BlickRezumatSubjectsDate bibliograficeCiteRelated studies

Abstract (original language)

Background

In South Africa, the metastatic response rate for stage 4 high-risk neuroblastoma (HR-NB) to induction chemotherapy is lower than that of similar regimens in well-resourced settings. Augmenting current induction chemotherapy regimens with molecular radiotherapy, without increasing toxicity, is an attractive systemic treatment in radioisotope-avid tumors, especially in a resource-limited setting where stem cell transplantation and immunotherapy are unavailable and costly. Clinical trials of [ 177 Lu]Lutetium DOTATATE ([ 177 Lu]Lu-DOTATATE) have primarily focused on refractory or relapsed HR-NB, with disappointing results. This study evaluates the feasibility and dose-limiting toxicity grading of adding a single dose of [ 177 Lu]Lu-DOTATATE to induction chemotherapy in achieving metastatic remission rates.

Objective

The aim of the proof-of-concept, open-label study is to evaluate the safety and efficacy of induction [ 177 Lu]Lu-DOTATATE peptide receptor radionuclide therapy (PRRT) on postinduction response rate in children diagnosed with HR-NB. The primary objectives are to evaluate the dose-limiting toxicity profile of participants treated with induction [ 177 Lu]Lu-DOTATATE PRRT in conjunction with standard induction chemotherapy; to evaluate the dosimetry in South African patients receiving induction [ 177 Lu]Lu-DOTATATE PRRT; and to evaluate the feasibility related to resources in patients treated with induction [ 177 Lu]Lu-DOTATATE PRRT in conjunction with standard induction chemotherapy. The secondary objective is to determine the postinduction metastatic response rate in patients diagnosed with HR-NB after receiving induction [ 177 Lu]Lu-DOTATATE PRRT in conjunction with standard induction chemotherapy.

Methods

The LuDO-SA trial is a phase 1, open-label, multicenter, 2-arm, randomized controlled clinical trial. Children aged 18 months to 18 years are eligible. The experimental arm, consisting of a single dose of [ 177 Lu]Lu-DOTATATE after cycle 1 of OJEC (vincristine, carboplatin, etoposide, and cyclophosphamide) and OPEC (vincristine, cisplatin, etoposide, and cyclophosphamide) chemotherapy, will be compared to the standard arm of OJEC and OPEC chemotherapy. The postinduction metastatic response rate is based on the International Neuroblastoma Response Criteria (INRC). The statistical analysis will be descriptive. The Fisher exact test will be used to evaluate the significance of end-of-trial outcomes.

Results

The trial received institutional ethics approval from 4 South African universities in 2022 and SAHPRA (South African Health Products Regulatory Authority) regulatory approval. The trial, funded by Kinderkankerfonds vzw and the UZA Foundation, commenced recruitment in January 2023. As of July 2026, a total of 15 patients have been enrolled across 4 academic hospital sites. Recruitment is projected to be completed by June 2027, with results expected to be published in December 2027.

Conclusions

In this paper, we present the protocol of the LuDO-SA trial. The rationale and design of the trial in a resource-limited setting and its use in first-line regimens are discussed, and the current status of international [ 177 Lu]Lu-DOTATATE molecular radiotherapy trials is summarized.

Subjects

MeSH terms (MEDLINE)

NeuroblastomaOctreotideInduction ChemotherapyOrganometallic CompoundsHumansSouth AfricaChild, PreschoolChildClinical Trials, Phase I as TopicFemaleInfantRandomized Controlled Trials as TopicMaleAntineoplastic Combined Chemotherapy ProtocolsEtoposide

Author keywords

PRRTSouth Africa[177Lu]Lutetium DOTATATEfirst-line therapyhigh-riskmetastatic remissionneuroblastomapeptide receptor radionuclide therapyradiopharmaceutical

Substances

Octreotidelutetium Lu 177 dotatateOrganometallic CompoundsEtoposide

Authors and institutions

  • Department of Paediatrics and Child Health, Faculty of Medicine and Health Sciences, Tygerberg Hospital, Stellenbosch University, Stellenbosch University, Tygerberg Campus, Francie van Zijl Drive, Cape Town, Western Cap…
  • Department of Paediatric Haemato-Oncology, MIPRO laboratory, Antwerp University Hospital, University of Antwerp, Antwerp Province, Belgium.
  • School of Psychology, University of KwaZulu-Natal, Pietermaritzburg, KwaZulu-Natal, South Africa.
  • Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp Province, Belgium.
  • Department of Paediatric Haemato-Oncology, Department of Paediatrics and Child Health, Inkosi Albert Luthuli Central Hospital, University of Kwa-Zulu Natal, Durban, KwaZulu-Natal, South Africa.
  • Department of Nuclear Medicine, Faculty of Medicine and Health Sciences, Tygerberg Hospital, Stellenbosch University, Cape Town, Western Cape, South Africa.

Cite

APA

van Heerden, J., Kruger, M., Reddy, K., van Zyl, A., Warwick, J., Burger, C., Moalosi, T., van Reenen, C., Davidson, A., Hlongwa, K., Violante, D., Bruwer, N., Naidu, G., Rowe, B., Louw, L., van Wyk, B., Vorster, M., Mkhize, T., & Brink, A. (2026). [177Lu]Lu-DOTATATE Molecular Radiotherapy During Induction Chemotherapy for First-Line Stage 4 High-Risk Neuroblastoma in South African Children: Protocol for a Phase 1 Randomized Controlled Trial (LuDO-SA Trial). JMIR Research Protocols, 15, e93547-e93547. https://doi.org/10.2196/93547

Vancouver

van Heerden J, Kruger M, Reddy K, van Zyl A, Warwick J, Burger C, et al. [177Lu]Lu-DOTATATE Molecular Radiotherapy During Induction Chemotherapy for First-Line Stage 4 High-Risk Neuroblastoma in South African Children: Protocol for a Phase 1 Randomized Controlled Trial (LuDO-SA Trial). JMIR Research Protocols. 2026;15:e93547-e93547. doi:10.2196/93547

BibTeX
@article{vanHeerden2026,
  author = {van Heerden, Jaques and Kruger, Mariana and Reddy, Kershinee and van Zyl, Anel and Warwick, James and Burger, Celeste and Moalosi, Tumelo and van Reenen, Christoffel and Davidson, Alan and Hlongwa, Khanyisile and Violante, Daniella and Bruwer, Nanette and Naidu, Gita and Rowe, Biance and Louw, Lizette and van Wyk, Bronwin and Vorster, Mariza and Mkhize, Thokozani and Brink, Anita},
  title = {[177Lu]Lu-DOTATATE Molecular Radiotherapy During Induction Chemotherapy for First-Line Stage 4 High-Risk Neuroblastoma in South African Children: Protocol for a Phase 1 Randomized Controlled Trial (LuDO-SA Trial)},
  journal = {JMIR Research Protocols},
  year = {2026},
  volume = {15},
  pages = {e93547--e93547},
  doi = {10.2196/93547}
}
Start for free →